


Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the present application:

1. (Currently amended) A pharmaceutical composition comprising a compound having the following formula (I):




wherein:

- (a) X is CH or N;
- (b) R₁ is hydrogen, alkyl, ~~aralkyl~~ aralkyl, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;
- (c) R₂ is hydrogen, alkyl, ~~aralkyl~~ aralkyl, aryl, or heteroaryl;
- (d) R_{2'} is hydrogen unless R₂ is methyl, in which case R_{2'} is also methyl;
- (e) R₃ has the following formula (III):



wherein:

- (i) R_4 is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;
- (ii) R_5 is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;
- (iii) R_6 is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;
- (iv) R_4 and R_5 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;
- (v) R_5 and R_6 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;
- (f) L is selected from the group consisting of $-(CH_2)_m-$, where m is an integer from 1 to 6, and an alkyl substituted hydrocarbonyl moiety of the formula (IV):



wherein:

- (i) n is 0, 1 or 2;
- (ii) R_7 and R_8 are hydrogen, methyl or ethyl;
- (iii) R_9 and R_9' are both hydrogen, methyl or ethyl;
- (iv) if n is 1 and R_7 or R_8 is methyl or ethyl, then R_9 and R_9' are hydrogen;

(v) if n is 1 and R₇ and R₈ are hydrogen, then R₉ and R₉' are methyl or ethyl; and

(vi) if n is 2, then R₉ and R₉' are hydrogen and one or both of R₇ and R₈ are methyl or ethyl.

and pharmaceutically acceptable salts and esters thereof.

2. (Original) The pharmaceutical composition of claim 1, wherein R₂ and R₂', are both hydrogen.
3. (Original) The pharmaceutical composition of claim 1, wherein R₄ is selected from the group consisting of hydrogen, halo, and alkoxy.
4. (Currently amended) The pharmaceutical composition of claim 1, wherein R₅ is selected from the group consisting of hydrogen, alkyl, halo, alkoxy, and perfluoroalkyl [[:]] .
5. (Original) The pharmaceutical composition of claim 1, wherein R₆ is selected from the group consisting of alkyl, halo, alkoxy, and perfluoroalkyl.
6. (Currently amended) The pharmaceutical composition of claim 1, wherein R₄ and R₅ ~~when taken~~ together form a naphthalene ring ~~÷ and~~ .
7. (Original) The pharmaceutical composition of claim 1, wherein R₅ and R₆ when taken together are selected from the group consisting of a methylenedioxy group and an ethylenedioxy group.
8. (Original) The pharmaceutical composition of claim 1, wherein L is an alkyl substituted hydrocarbyl moiety of formula (IV).
9. (Original) The pharmaceutical composition of claim 1, comprising a pharmaceutically acceptable excipient.

10. (Withdrawn) A method of treating a psychiatric or neurological condition, comprising the step of administering a therapeutic dose of the pharmaceutical composition of claim 1 to a patient in need thereof.
11. (Withdrawn) The method of claim 10, wherein the therapeutic dose is administered by an administrative route selected from the group consisting of intravenous infusion, oral, topical, intraperitoneal, intravesical, transdermal, nasal, rectal, vaginal, intramuscular, intradermal, subcutaneous and intrathecal routes.
12. (Withdrawn) The method of claim 10, wherein the therapeutic dose is in the range of 0.0001 mg/kg to 60 mg/kg.
13. (Withdrawn) The method of claim 10, wherein the condition being treated is a psychiatric condition.
14. (Withdrawn) The method of claim 10, wherein the condition being treated is pain.
15. (Withdrawn) The method of claim 10, wherein the condition being treated is emesis.
16. (Withdrawn) The method of claim 10, wherein the condition being treated is neurodegeneration.

Claims 17-18 (canceled).

19. (Previously presented) The pharmaceutical composition of claim 1, wherein the compound is selected from the group consisting of:

1-{4-[4-(4-Fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
1-{3-[4-(3,4-Dichlorophenyl)piperazin-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one;
1-{4-[4-(2,4-Dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
1-{4-[4-(3-Chloro-4-fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;
1-{4-[4-(4-Bromophenyl)piperazine-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one; and
1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one

20. (Previously presented) The pharmaceutical composition of claim 19, wherein the compound is 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.
21. (Withdrawn) The method of claim 10, wherein the pharmaceutical composition comprises 1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.
22. (New) The pharmaceutical composition of claim 5, wherein R₆ is halo.
23. (New) The pharmaceutical composition of claim 22, wherein R₅ and R₆ are halo.
24. (New) The pharmaceutical composition of claim 1, wherein R₆ is C₂-C₁₀ alkyl.
25. (New) A method of treating a psychiatric or neurological condition, comprising the step of administering a therapeutic dose of the pharmaceutical composition of claim 19 to a patient in need thereof.